when should we start using angiotensin converting enzyme inhibitors/angiotensin receptor blockers in diabetic kidney disease?
Clicks: 265
ID: 175029
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
265 views
48 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #16 of 39 articles by views in oncology letters
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
International guidelines do not recommend angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) usage in the first stage of diabetic kidney disease. It shows the view, based on a small statistical sample, that olmesartan (or possibly other ACE inhibitors/ARBs) should be used to prevent the transition of the first stage of diabetic kidney disease to the second one in type 2 diabetes mellitus.
| Reference Key |
ivanov2017pokiwhen
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;D.D. Ivanov |
| Journal | oncology letters |
| Year | 2017 |
| DOI |
10.22141/2307-1257.6.1.2017.93781
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.